Luigi Gugliotta
Overview
Explore the profile of Luigi Gugliotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzucconi M, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, et al.
Blood Adv
. 2024 Jan;
8(6):1529-1540.
PMID: 38231017
A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia...
2.
Birgegard G, Folkvaljon F, Garmo H, Holmberg L, Besses C, Griesshammer M, et al.
Leuk Res
. 2018 Oct;
74:105-109.
PMID: 30368038
EXELS, a post-marketing observational study, is the largest prospective study of high-risk essential thrombocythemia (ET) patients, with an observation time of 5 years. EXELS found higher event rates of acute...
3.
Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison C, Hamdani M, et al.
Haematologica
. 2017 Oct;
103(1):51-60.
PMID: 29079600
Evaluation of Anagrelide (Xagrid) Efficacy and Long-term Safety, a phase IV, prospective, non-interventional study performed in 13 European countries enrolled high-risk essential thrombocythemia patients treated with cytoreductive therapy. The primary...
4.
Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, et al.
Leuk Res
. 2016 Apr;
46:18-25.
PMID: 27107744
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics...
5.
Cozzani E, Iurlo A, Merlo G, Cattaneo D, Burlando M, Pierri I, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Oct;
15(12):739-47.
PMID: 26432058
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increase in blood platelets and dominated by a predisposition to vascular events. Cutaneous manifestations can complicate its course. itching has...
6.
Tortorella G, Piccin A, Tieghi A, Marcheselli L, Steurer M, Gastl G, et al.
Leuk Res
. 2015 Apr;
39(6):592-8.
PMID: 25850727
In this prospective observational single-center study, 55 patients with essential thrombocythemia who were candidates for second line treatment with anagrelide (ANA) received a preliminary cardiovascular (CV) clinical, instrumental and biochemical...
7.
Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian J, Coll R, et al.
Haematologica
. 2013 Dec;
99(4):679-87.
PMID: 24334294
Available information is limited regarding the use of cytoreductive combination therapy in high-risk patients with essential thrombocythemia. This analysis aims to evaluate the clinical relevance and patterns of cytoreductive combination...
8.
Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E, et al.
Mod Pathol
. 2013 Nov;
27(6):814-22.
PMID: 24201120
This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocitemie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO classification for...
9.
Besses C, Kiladjian J, Griesshammer M, Gugliotta L, Harrison C, Coll R, et al.
Leuk Res
. 2012 Dec;
37(2):162-8.
PMID: 23199894
EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of...
10.
Kiladjian J, Besses C, Griesshammer M, Gugliotta L, Harrison C, Coll R, et al.
Clin Drug Investig
. 2012 Nov;
33(1):55-63.
PMID: 23184668
Background: The median age of patients diagnosed with essential thrombocythaemia (ET) is 65-70 years but the management of very elderly patients (aged >80 years) with ET has not been well...